Citicoline - a neuroprotector with proven effects on glaucomatous disease - PubMed (original) (raw)

Review

Citicoline - a neuroprotector with proven effects on glaucomatous disease

Chitu Iulia et al. Rom J Ophthalmol. 2017 Jul-Sep.

Abstract

Citicoline is the generic name of cytidine-5'-diphosphocholine (CDP-choline), an endogenous compound that is able to increase the levels of neurotransmitters in the central nervous system by interacting with the synthesis of cellular membranes phospholipids, especially phosphatidylcholine. Exogenous Citicoline, administered by ingestion or injection, is hydrolyzed and dephosphorylated in order to form cytidine and choline, which resynthesize CDP-choline inside brain cells. It has proven neuroprotective effects in Alzheimer disease, stroke, and Parkinson's disease, as well as in glaucoma and amblyopia. Citicoline acts as a neuroprotector for those patients with progressive glaucomatous disease in spite of well-controlled intraocular pressure. The purpose of this review was to outline the main features of Citicoline and the evidences of its effect in glaucoma.

Keywords: Citicoline; glaucoma; neuroprotection.

PubMed Disclaimer

Figures

Fig. 1

Fig. 1

Chemical structure of Citicoline

Fig. 2

Fig. 2

The CDP-choline pathway

Fig. 3

Fig. 3

Transverse sections in rat retina at 7 days after KA injection using H-E staining. In control retina, five, well organized retinal layers are seen (A). In the KA-injected group, the thickness of retina is markedly reduced due to loss of internal nuclear (INL) and internal plexiform layers (IPL) (B). Conserved retinal layers in KA-injected group treated with Citicoline (C)

Fig. 4

Fig. 4

Electrophysiological examination at baseline, after 60 days of treatment with Citicoline and after the last washout period. Improvement of visual field and electrophysiological parameters after treatment followed by regression or stabilization after washout [

]

Similar articles

Cited by

References

    1. Grieb P. Neuroprotective Properties of Citicoline: Facts, Doubts and Unresolved Issues. CNS Drugs. 2014;28(3):185–193. - PMC - PubMed
    1. Secades JJ. Citicoline: Pharmacological and clinical review, 2010 update. Revista de neurologie. 2011 Mar;52(Suppl 2):S1–S62. - PubMed
    1. Muralikrishna Adibhatla R, Hatcher JF, Dempsey RJ. Citicoline: neuroprotective mechanisms in cerebral ischemia. Journal of Neurochemistry. 2002;80:12–23. - PubMed
    1. Gutiérrez-Fernández M, Rodríguez-Frutos B, Fuentes B, Vallejo-Cremades MT, Alvarez-Grech J, Expósito-Alcaide M, Díez-Tejedor E. CDP-choline treatment induces brain plasticity markers expression inexperimental animal stroke. Neurochem. Int. 2012;60:310–317. - PubMed
    1. Cacabelos R, Caamaño J, Gómez MJ, Fernández-Novoa L, Franco-Maside A, Alvarez XA. Therapeutic effects of CDP-choline in Alzheimer’s disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors. Ann. N. Y. Acad. Sci. 1996;777:399–403. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources